YONG LI to Lymphoma, Large B-Cell, Diffuse
This is a "connection" page, showing publications YONG LI has written about Lymphoma, Large B-Cell, Diffuse.
Connection Strength
1.682
-
Prognostic stratification in DLBCL patients with aberrant MYC gene. Br J Haematol. 2024 Nov; 205(5):1782-1793.
Score: 0.185
-
DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphoma. Oncoimmunology. 2024; 13(1):2384667.
Score: 0.185
-
Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL. Clin Cancer Res. 2023 12 01; 29(23):4808-4821.
Score: 0.176
-
Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2022 Mar 01; 28(5):972-983.
Score: 0.156
-
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. Blood Cancer J. 2022 02 01; 12(2):25.
Score: 0.155
-
Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. Mol Cancer Res. 2021 02; 19(2):249-260.
Score: 0.142
-
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. J Hematol Oncol. 2020 11 04; 13(1):148.
Score: 0.142
-
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. Blood Adv. 2020 07 28; 4(14):3391-3404.
Score: 0.140
-
Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. Blood Cancer J. 2020 05 04; 10(5):49.
Score: 0.137
-
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. J Immunother Cancer. 2019 10 22; 7(1):272.
Score: 0.132
-
Genetic alterations and their clinical implications in DLBCL. Nat Rev Clin Oncol. 2019 10; 16(10):634-652.
Score: 0.132